USE OF CRENOLANIB FOR TREATING ACUTE MYELOID LEUKEMIA (AML) RELATED TO FLT3 MUTATION, AND METHOD OF TREATMENT

摘要

The invention relates to the use of a composition comprising a therapeutically effective amount of crenolanib or a pharmaceutically acceptable salt thereof for the treatment of acute myeloid leukemia (AML) with FLT3 mutation and/or deregulated FLT3 receptor tyrosine kinase activity, as well as to a method of treating FLT3 mutated acute myeloid leukemia in a patient comprising administering a therapeutically effective amount of a composition comprising crenolanib or a salt thereof.